<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for metastatic hormone-refractory prostate cancer: Docetaxel and prednisone&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for metastatic hormone-refractory prostate cancer: Docetaxel and prednisone<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for metastatic hormone-refractory prostate cancer: Docetaxel and prednisone<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class="divider_bottom"> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose and route</td> <td class="subtitle1">Administration</td> <td class="subtitle1">Given on days</td> </tr> <tr> <td>Docetaxel</td> <td>75 mg/m<sup>2</sup> IV*</td> <td>Dilute in 250 mL normal saline and administer over one hour.</td> <td>Day 1</td> </tr> <tr class="divider_bottom"> <td>Prednisone</td> <td>5 mg orally</td> <td>Twice daily.</td> <td>Days 1 to 21</td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>LOW (10 to 30% frequency of emesis).</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reaction and fluid retention</strong></td> <td colspan="3"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.<sup>[2]</sup></li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Docetaxel is an irritant but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of febrile neutropenia approximately 3%<sup>[1]</sup>).</li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or kidney dysfunction</strong></td> <td colspan="3"> <ul> <li>Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times the ULN in conjunction with alkaline phosphatase &gt;2.5 times the ULN.<sup>[2]</sup></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan="3"> <ul> <li>Caution is required if administering docetaxel with strong CYP3A4 inhibitors.<sup>¶</sup> According to the United States Prescribing Information, avoid the use of docetaxel with strong CYP3A4 inhibitors (if possible). If concomitant therapy cannot be avoided, monitor closely for toxicity and consider a docetaxel dose reduction.<sup>[2]</sup> Docetaxel dose reductions for concomitant therapies should be individualized based on patient factors (eg, performance status) and the intent of therapy (ie, curative or palliative).</li> <li>Refer to "Suggested dose modifications for toxicity" below.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential at least every three weeks during treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Kidney and liver function testing at least every three weeks during treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for neurologic function and gastrointestinal toxicities.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Patients with kidney impairment, hyperuricemia, and bulky tumors are at risk for TLS and should undergo correction of dehydration and lowering of high serum uric acid levels prior to treatment initiation, and be closely monitored for TLS during and after treatment.</li> <li>Refer to UpToDate topics on tumor lysis syndrome.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Docetaxel should only be administered if the absolute neutrophil count is &gt;1500 cells/microL. Reduce docetaxel to 60 mg/m<sup>2</sup> for subsequent cycles for severe prolonged neutropenia (&lt;500 cells/microL lasting seven days or more), febrile neutropenia, or an infection with life-threatening consequences.<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cutaneous, mucosal, and neurologic toxicity</strong></td> <td colspan="3"> <ul> <li>For severe or cumulative cutaneous reactions (erythema, desquamation), grade 3 or 4 stomatitis or &gt;grade 2 neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup>.<sup>[1]</sup> Discontinue docetaxel if toxicity persists at the lower dose.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Hepatotoxicity</strong></td> <td colspan="3"> <ul> <li>Docetaxel dose reduction may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times the ULN in conjunction with alkaline phosphatase &gt;2.5 times the ULN.</li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="4"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes"><p>CBC: complete blood count; CYP3A4: cytochrome P450 3A4; IV: intravenous; TLS: tumor lysis syndrome; ULN: upper limit of normal.</p>
<p>* Some clinicians use a dose of 70 to 75 mg/m<sup>2</sup> to minimize toxicity.</p>
¶ A list of strong and moderate CYP3A4 inhibitors is available as a separate table in UpToDate. Specific interactions may be determined by use of the <a href="https://www.uptodate.com/drug-interactions" target="_blank">Lexicomp drug interactions</a> program included within UpToDate.</div><div class="graphic_reference">References:
<ol>
<li>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004; 351:1502.</li>
<li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://www.dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 15, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 57477 Version 19.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
